| Abstract | The administration of milrinone through inhalation has been studied in only a few animal and human studies. Compared to the intravenous administration, inhaled milrinone has been shown to reduce pulmonary artery pressure without systemic hypotension. Therefore, this approach could represent an alternative to nitric oxide. This current state of knowledge of intravenous and inhaled milrinone is presented and summarized. |
| Authors | André Y Denault, Yoan Lamarche, Pierre Couture, Francois Haddad, Jean Lambert, Jean-Claude Tardif, Louis P Perrault
(Affiliation: Department of Cardiac Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. denault at videotron.ca)
|
| Journal | Seminars in cardiothoracic and vascular anesthesia
(Semin Cardiothorac Vasc Anesth)
Vol. 10
Issue 4
Pg. 346-60
(Dec 2006)
ISSN: 1089-2532 United States |
| PMID | 17200091
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
| Chemical References |
- Phosphodiesterase Inhibitors
- Milrinone
|
| Topics |
- Administration, Inhalation
- Animals
- Endpoint Determination
(methods)
- Heart Function Tests
- Humans
- Hypertension, Pulmonary
(drug therapy, etiology, physiopathology)
- Injections, Intravenous
- Milrinone
(administration & dosage, pharmacology)
- Monitoring, Physiologic
- Phosphodiesterase Inhibitors
(administration & dosage, pharmacology)
- Swine
- Thoracic Surgical Procedures
(adverse effects)
- Treatment Outcome
|
